Cardiac transplant experience with cyclosporine

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S323-S330

  Patel, J K ^a   Kobashigawa, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHILIN; CYCLOSPORIN A; EVEROLIMUS; HYDANTOIN DERIVATIVE; INTERLEUKIN 2; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GINGIVA HYPERPLASIA; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART GRAFT; HEART TRANSPLANTATION; HEMOLYTIC ANEMIA; HERPES; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERVOLEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; KAPOSI SARCOMA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICROEMULSION; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMOCYSTOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEIZURE; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; VASCULAR DISEASE; VIRUS HEPATITIS;

EID: 1642271438     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.039     Document Type: Article

References (64)

1. Caves P.K., Stinson E.B., Griepp R.B., et al. Results of 54 cardiac transplants. Surgery. 74:1973;307.
2. Borel J.F., Feurer C., Magnee C., et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 32:1977;1017.
3. Griffith B.P., Hardesty R.L., Deeb G.M., et al. Cardiac transplantation with cyclosporin A and prednisone. Ann Surg. 196:1982;324.
4. Oyer P., Stinson E., Jamieson S., et al. Cyclosporine in cardiac transplantation a 2 1/2 year follow-up. Transplant Proc. 15:1983;2546.
5. Cooley D., Frazier O., Painvin G., et al. Cardiac and cardiopulmonary transplantation using cyclosporine for immunosuppression recent Texas Heart Institute experience. Transplant Proc. 15:1983;2567.
6. Wallwork J., Cory-Pearce R., English T. Cyclosporine for cardiac transplantation. Transplant Proc. 15:1983;2559.
7. Cheung A., Menkis A.H. Cyclosporine heart transplantation. Transplant Proc. 30:1998;1881.
8. Opelz G. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study. Transplant Proc. 29:1997;617.
9. Grattan M., Moreno-Cabral C., Starnes V., et al. Eight-year results of cyclosporine-treated patients with cardiac transplants. J Thorac Cardiovasc Surg. 99:1990;500.
10. Kronke M., Leonard W.J., Depper J.M., et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Nati Acad Sci U S A. 81:1984;5214.
11. Herold K.C., Lancki D.W., Moldwin R.L., et al. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol. 136:1986;1315.
12. Granelli-Piperno A. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med. 168:1988;1649.
13. Shibasaki F., Price E.R., Milan D., et al. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature. 382:1996;370.
14. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family regulation and function. Ann Rev Immunol. 15:1997;707.
15. Rincon M., Flavell R.A. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 13:1994;4370.
16. Metcalfe S., Alexander D., Turner J. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. Cell Immunol. 158:1994;46.
17. Matsuda S., Moriguchi T., Koyasu S., et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem. 273:1998;12378.
18. Cooney G.F., Jeevanandam V., Choudhury S., et al. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year. Transplant Proc. 30:1998;1892.
19. Eisen H.J., Hobbs R.E., Davis S.F., et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation. Transplantation. 71:2001;70.
20. Carrier M., White M., Pellerin M., et al. Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. Can J Cardiol. 13:1997;469.
21. Maccherini M., Bernazzali S., Diciolla F., et al. Neoral versus Sandimmun clinical impact and modification of immunosuppressive therapy in cardiac transplantation. Transplant Proc. 30:1998;1904.
22. Yonan N.A., Aziz T., el-Gamel A., et al. Long-term safety and efficacy of Neoral in heart transplantation. Transplant Proc. 30:1998;1906.
23. Keevil B.G., Tierney D.P., Cooper D.P., et al. Rapid liquid chromatography-tandem mass spectrometry method for routine analysis of cyclosporin A over an extended concentration range. Clin Chem. 48:2002;69.
24. Soldin S.J., Steele B.W., Witte D.L., et al. Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med. 127:2003;19.
25. Kahan B.D., Keown P., Levy G.A., et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 24:2002;330.
26. Keown P., Landsberg D., Halloran P., et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 62:1996;1744.
27. Laine J., Hoppu K., Jalanko H., et al. Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts. Transplantation. 63:1997;1768.
28. Halloran P.F., Helms L.M., Kung L., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 8:1999;1356.
29. Stein C.M., Murray J.J., Wood A.J. Inhibition of stimulated interleukin-2 production in whole blood a practical measure of cyclosporine effect. Clin Chem. 45:1999;1477.
30. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 68:1999;55.
31. Cantarovich M., Elstein E., de Varennes B., et al. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 68:1999;1839.
32. Ventura H.O., Malik F.S., Mehra M.R., et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 12:1997;375.
33. Kobashigawa J.A., Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation. 63:1997;331.
34. Kim J.H., Perfect J.R. Infection and cyclosporine. Rev Infect Dis. 11:1989;677.
35. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:1999;530.
36. Calne R.Y., Rolles K., White D.J., et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs 32 kidneys, 2 pancreases, and 2 livers. Lancet. 2:1979;1033.
37. Opelz G., Schwarz V., Henderson R., et al. Non-Hodgkin's lymphoma after kidney or heart transplantation frequency of occurrence during the first posttransplant year. Transpl Int. 7:(Suppl 1):1994;S353.
38. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1:1984;583.
39. Swinnen LJ: Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. J Natl Cancer Inst Monogr 28:38, 2001.
40. Opelz G., Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 342:1993;1514.
41. Penn I. Posttransplant malignancies. Transplant Proc. 31:1999;1260.
42. Klintmalm G.B., Iwatsuki S., Starzl T.E. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation. 32:1981;488.
43. Cadranel J.F., Grippon P., Mattei M.F., et al. Prevalence and causes of long-lasting hepatic dysfunction after heart transplantation a series of 80 patients. Artif Organs. 12:1988;234.
44. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 33:1988;590.
45. Satchithananda D.K., Parameshwar J., Sharples L., et al. The incidence of end-stage renal failure in 17 years of heart transplantation a single center experience. J Heart Lung Transplant. 21:2002;651.
46. van Gelder T., Balk A.H., Zietse R., et al. Survival of heart transplant recipients with cyclosporine-induced renal insufficiency. Transplant Proc. 30:1998;1122.
47. Hartmann A., Andereassen A.K., Holdaas H., et al. Five years' follow-up of renal glomerular and tubular functions in heart transplant recipients. J Heart Lung Transplant. 15:1996;972.
48. Aleksic I., Baryalei M., Busch T., et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation. 69:2000;1586.
49. Paller M.S., Murray B.M. Renal dysfunction in animal models of cyclosporine toxicity. Transplant Proc. 17:1985;155.
50. Woolfson R.G., Neild G.H. Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant. 12:1997;2054.
51. Braith R.W., Mills R.M., Wilcox C.S., et al. High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol. 41:2003;426.
52. Hansen J.M., Christensen N.J., Fogh-Andersen N., et al. Effects of the prostacyclin analogue iloprost on cyclosporin-induced renal hypoperfusion in stable renal transplant recipients. Nephrol Dial Transplant. 11:1996;340.
53. Johnson D.W., Saunders H.J., Johnson F.J., et al. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther. 289:1999;535.
54. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 66:1998;507.
55. Taylor D.O., Barr M.L., Radovancevic B., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 18:1999;336.
56. Reichart B., Meiser B., Vigano M., et al. European multicenter tacrolimus heart pilot study three year follow-up. J Heart Lung Transplant. 20:2001;249.
57. Armitage J.M., Kormos R.L., Morita S., et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 54:1992;205.
58. Mentzer R.M. Jr, Jahania M.S., Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation. 65:1998;109.
59. Meiser B.M., Uberfuhr P., Fuchs A., et al. Tacrolimus a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant. 16:1997;795.
60. Taylor D.O., Barr M.L., Meiser B.M., et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant. 20:2001;734.
61. Radovancevic B., Vrtovec B. Sirolimus therapy in cardiac transplantation. Transplant Proc. 35:2003;S171.
62. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 108:2003;48.
63. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 349:2003;847.
64. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 76:2003;364.